And so this represented a 41% relative risk reduction in that first 24 weeks for ARIA-E for the modified titration, and that achieved that with a probability of 94%. So in summary, this 24-week ...

Continuous acoramidis use resulted in a 48.2% reduction in relative risk of all-cause mortality or recurrent cardiovascular hospitalizations through 42 months. The FDA approved acoramidis for ATTR ...